Investor Presentation Full Year 2017
Investor Presentation
Full year 2017
Slide 94
Strong growth among long-acting haemophilia B products
as Refixia®/RebinynⓇ is set for launch in the EU and the USA
Reported recombinant FIX sales
Sales
(USD million)
1,200
1,000
800
600
400
200-
0
2011
Benefix®
AlprolixⓇ
CAGR: +10%
IdelvionⓇ
•
2016
.
RefixiaⓇ/RebinynⓇ launched in first countries
Launched in the first EU countries in 2017, US launch
expected in the first quarter of 2018
RefixiaⓇ/RebinynⓇ offers a unique clinical profile that brings
factor levels into the non-haemophilia range for adults and
adolescents
• Dialogue ongoing with the FDA and EMA to establish path
forward to obtain routine prophylaxis indication in the USA
and complete paediatric indication in Europe to include
children younger than 12 years old
FIX: Coagulation factor IX
Source: Company reports (Does not include RixubisⓇ as sales are not reported separately)
changing
diabetes®
FDA: US Food and Drug Administration; EMA: European Medicines Agency
rFIX: Recombinant coagulation factor IX
novo nordiskView entire presentation